HC9 Ventures

Hank Cauley, the firm's Managing Partner and founder, leads all investment decisions. He previously served as Chief Investment Officer of Kensington Capital, a captive venture and growth-equity arm inside a publicly traded insurance company, where he built a direct-investment track record across enterprise software and energy-transition sectors. HC9 operates with a centralized investment committee structure under Cauley's authority.

Deal flow originates primarily through Cauley's insurance-industry network and the firm's LP base, which consists of senior executives from regulated financial institutions and insurance carriers. HC9 frequently enters rounds where a corporate strategic or insurance-adjacent co-investor has already conducted diligence, reducing the adverse-selection risk common in early-stage enterprise investing. The firm does not operate a public scout network or accelerator program.

HC9 invests from Seed through late-stage venture, with initial check sizes typically ranging from $1 million to $5 million. The firm reserves capital for follow-on investments in portfolio companies that demonstrate enterprise-adoption traction. Stage allocation is driven by company-specific milestones rather than rigid portfolio-construction targets.

HC9 concentrates on enterprise software, digital health, climate technology, AI/ML applications, and financial services — sectors where regulatory complexity and slow procurement cycles create moats that consumer-focused investors rarely underwrite. The firm avoids direct-to-consumer businesses, hardware-heavy industrial plays, and biotechnology companies that carry binary FDA risk.

HC9 raised its capital from principals whose wealth originates inside insurance balance sheets and regulated financial institutions, not from endowments or fund-of-funds aggregators. This LP composition gives the firm a patient-capital mandate — its backers understand multi-year enterprise sales cycles and regulatory timelines. The fund does not publicly disclose AUM or individual LP identities.

HC9 typically co-invests alongside corporate strategics or insurance-industry investors who lead the diligence process, rather than competing for lead-investor position. The firm will, however, lead or co-lead seed rounds where Cauley's domain expertise — particularly in insurtech or enterprise data infrastructure — gives HC9 an information advantage over generalist funds.

HC9 is US-focused, with portfolio companies concentrated in the Northeast and California technology corridors. The firm's Woodstock, New York headquarters places it within driving distance of Boston, New York City, and the Northeast insurtech ecosystem, while California exposure comes through venture-syndicate relationships rather than a dedicated West Coast office.